建立新的可预测成年终身高及青春期进程的模型及其在特发性中枢性性早熟女童中的应用(1)
[摘要] 目的 探讨建立新的可预测成年终身高及青春期进程的模型及其在特发性中枢性性早熟女童中的应用。 方法 通过对 2005年1月1日～2015年12月31日在我院治疗并随访至成年身高的特发性中枢性性早熟女性患儿进行召回。符合ICPP资料齐全的患儿共303例，正规接受GnRHa治疗共253例，未接受治疗共50例。将253例治疗组患者根据首次治疗年龄分为低年龄组A组：治疗时间≤7岁及高年龄组B组：治疗时间>7岁，共211例，其中B1考虑快速进展型(LH>10.05或LH峰值/FSH峰值>0.6)共159例，B2考虑非快速进展型共52例。未治疗组C组，共50例。比较各组身高改善情况。 结果 GnRHa治疗组较未治疗组最终身高有改善，差异有统计学意义(P<0.05)。A组予GnRHa治疗身高改善更明显，差异有统计学意义(P<0.05)。B1快速进展型予GnRHa治疗身高改善更明显，差异有统计学意义(P<0.05)。 结论 应用 GnRHa治疗特发性中枢性性早熟对于预测成年终身高疗效确切，尤其对于低年龄、快速进展型效果更好。
[关键词] 中枢性性早熟；GnRHa；rhGH；快速进展型
[中图分类号] R725.8 [文献标识码] B [文章编号] 1673-9701(2018)04-0098-03
[Abstract] Objective To explore the establishment of a new predictable model of adult final height and puberty progress and its application in the girls with idiopathic central precocious puberty. Methods The girls with idiopathic central precocious puberty who were treated and followed up until the adult height in our hospital from January 1， 2005 to December 31， 2015 were recalled. There were 303 cases of girls in line with complete ICPP data. A total of 253 patients were formally given GnRHa therapy， a total of 50 patients did not receive treatment. According to the initial treatment age， 253 patients in the treatment group were divided into the lower age group A： treatment time was≤7 years old， and higher age group B： treatment time was >7 years old， with a total of 211 cases. Group B1 considered rapid progress(LH>10.05 or LH peak/FSH peak>0.6)， with a total of 159 cases. Group B2 considered non-rapid progress， with a total of 52 cases. Untreated group was group C， with a total of 50 cases. The height improvement in each group was compared. Results The final height of the girls receiving GnRHa treatment group was improved compared with the untreated group， and the difference was statistically significant(P<0.05). Group A was given GnRHa treatment， and the height improvement was more obvious. The difference was statistically significant(P<0.05). B1 rapid progress group was given GnRHa treatment and the height improvement was more obvious. The difference was statistically significant(P<0.05). Conclusion The application of GnRHa in the treatment of idiopathic central precocious puberty has an exact effect on predicting adult final height， especially for lower age and rapid progress， which has a better effect.
[Key words] Central precocious puberty； GnRHa； rhGH； Rapid progress
中樞性性早熟(idiopathic central precocious puberty，ICPP)是指由于下丘脑-垂体-性腺轴(hypothalamic-pituitary-gonadal axis，HPGA)功能提前启动而导致女孩8岁前、男孩9岁前出现内外生殖器官快速发育及第二性征呈现的一种常见的儿科内分泌疾病，发病率约1/5000～1/10000，女孩约为男孩的5～10倍[1-3]。促性腺激素释放激素类似物(GnRHa)为目前治疗CPP的常用药物，其主要的治疗目的是改善儿童的最终成年身高[4，5]，本研究旨在探讨建立新的可预测成年终身高及青春期进程的模型及促性腺激素释放激素类似物在特发性中枢性性早熟女童中的应用，现报道如下。, http://www.100md.com(卢一丽 金佳蕙 单小鸥)
[关键词] 中枢性性早熟；GnRHa；rhGH；快速进展型
[中图分类号] R725.8 [文献标识码] B [文章编号] 1673-9701(2018)04-0098-03
[Abstract] Objective To explore the establishment of a new predictable model of adult final height and puberty progress and its application in the girls with idiopathic central precocious puberty. Methods The girls with idiopathic central precocious puberty who were treated and followed up until the adult height in our hospital from January 1， 2005 to December 31， 2015 were recalled. There were 303 cases of girls in line with complete ICPP data. A total of 253 patients were formally given GnRHa therapy， a total of 50 patients did not receive treatment. According to the initial treatment age， 253 patients in the treatment group were divided into the lower age group A： treatment time was≤7 years old， and higher age group B： treatment time was >7 years old， with a total of 211 cases. Group B1 considered rapid progress(LH>10.05 or LH peak/FSH peak>0.6)， with a total of 159 cases. Group B2 considered non-rapid progress， with a total of 52 cases. Untreated group was group C， with a total of 50 cases. The height improvement in each group was compared. Results The final height of the girls receiving GnRHa treatment group was improved compared with the untreated group， and the difference was statistically significant(P<0.05). Group A was given GnRHa treatment， and the height improvement was more obvious. The difference was statistically significant(P<0.05). B1 rapid progress group was given GnRHa treatment and the height improvement was more obvious. The difference was statistically significant(P<0.05). Conclusion The application of GnRHa in the treatment of idiopathic central precocious puberty has an exact effect on predicting adult final height， especially for lower age and rapid progress， which has a better effect.
[Key words] Central precocious puberty； GnRHa； rhGH； Rapid progress
中樞性性早熟(idiopathic central precocious puberty，ICPP)是指由于下丘脑-垂体-性腺轴(hypothalamic-pituitary-gonadal axis，HPGA)功能提前启动而导致女孩8岁前、男孩9岁前出现内外生殖器官快速发育及第二性征呈现的一种常见的儿科内分泌疾病，发病率约1/5000～1/10000，女孩约为男孩的5～10倍[1-3]。促性腺激素释放激素类似物(GnRHa)为目前治疗CPP的常用药物，其主要的治疗目的是改善儿童的最终成年身高[4，5]，本研究旨在探讨建立新的可预测成年终身高及青春期进程的模型及促性腺激素释放激素类似物在特发性中枢性性早熟女童中的应用，现报道如下。, http://www.100md.com(卢一丽 金佳蕙 单小鸥)